



Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0

Guest Editors:

Dr. Byeong Hwa Jeon

Department of Physiology,
Chungnam National University,
Daejeon, Republic of Korea

Dr. Hee Kyoung Joo

1. Research Institute for Medical
Sciences, College of Medicine,
Chungnam National University,
266 Munhwa-ro, Jung-gu,
Daejeon 35015, Republic of Korea
2. Department of Physiology,
College of Medicine, Chungnam
National University, 266 Munhwa-
ro, Jung-gu, Daejeon 35015,
Republic of Korea

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editors

Dear Colleagues,

The Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0”, will focus on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions related to vascular inflammation.

The pathophysiology of endothelial dysfunction (ED) is complex, and multifactorial factors are involved, such as oxidative stress or chronic inflammation. This Special Issue is open for a wide range of basic to preclinical research studies, or those adopting a multidisciplinary approach, and will also cover original articles and reviews on the following topics:

Target molecules or pathophysiology

Primary prevention of cardiovascular risk factors

Early detection or molecular imaging techniques

New therapeutic approaches including biomaterials
development

Drug delivery systems

Immunology and tumor environments

Dr. Byeong Hwa Jeon

Dr. Hee Kyoung Joo

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)